ArticleOral oncology2017

IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer.

L P Stabile et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.